Consistently, CRIP1 depletion significantly suppressed tumor growth and reduced tumor burden in docetaxel-treated LNCaP-DTXr xenografts, indicating restored chemosensitivity <i>in vivo</i>. The gene discussed is CRIP1; the disease is neoplasm.